
Hyperfine (HYPR) Stock Forecast & Price Target
Hyperfine (HYPR) Analyst Ratings
Bulls say
Hyperfine is attractive because its Model 2 Swoop system is gaining traction across hospitals, neurology offices, and international markets, with more than 200 systems deployed worldwide and 12 units sold in 2Q26, up 50% year over year. The business is showing improving unit economics and durability, with gross margin above 50% for four consecutive quarters, a 2026 revenue guide of $20M-$22M, and cash burn targeted to decline to $26M-$28M while cash of $43.5M supports runway into 2028. Its outlook is further strengthened by recurring software upgrades, a growing installed base that can drive service revenue, compelling 1-1.5 year hospital ROI, and contrast-label expansion progress that could widen clinical utility and accelerate adoption.
Bears say
Hyperfine is challenged by slow Swoop adoption, and its relatively small install base makes quarterly results lumpy if deployments take longer than expected. The business also faces meaningful cost and supply risk because Benchmark Electronics manufactures and ships the scanners and a single-source magnet supplier can pressure margins, while capital intensity leaves it dependent on favorable debt or equity markets to avoid dilution or liquidity strain. International expansion adds another layer of uncertainty, as geopolitical, regulatory, competitive, and market-acceptance hurdles could slow growth and weaken operating performance against larger MRI incumbents.
This aggregate rating is based on analysts' research of Hyperfine and is not a guaranteed prediction by Public.com or investment advice.
Hyperfine (HYPR) Analyst Forecast & Price Prediction
Start investing in Hyperfine (HYPR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Hyperfine (HYPR) Forecast
Hyperfine (HYPR) Analyst Forecast & Price Prediction
Start investing in Hyperfine (HYPR)
Order type
Buy in
Order amount
Est. shares
0 shares